H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Axsome Therapeutics to $180 from $190 and keeps a Buy rating on the shares. The company reported a Q2 sales miss but its commercial outlook still favorable, especially in depression, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Axsome Therapeutics Inc. (AXSM) Q2 Earnings Cheat Sheet
- Axsome Therapeutics initiated with a Buy at Needham
- Axsome Therapeutics price target lowered to $95 from $97 at BofA
- Biotech Alert: Searches spiking for these stocks today